Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Τετάρτη 19 Σεπτεμβρίου 2018

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)

Abstract

Introduction

There is an urgent need to identify patients with bladder cancer (BC) who are at high risk of recurrence or progression. Calgranulin A is a strong marker for muscle-invasive or advanced BC and recent studies have shown its potential for identifying patients at risk even in non-muscle-invasive bladder cancer (NMIBC). The present study examines risks of recurrence and progression dependent on immunostaining with calgranulin A in NMIBC.

Methods

Calgranulin A protein expression was evaluated through the immunohistochemistry of 158 randomly selected, transurethrally resected BC specimens of separate patients (pTa 89, pT1 69) using tissue microarrays. Kaplan–Meier survival analysis and Cox regression were performed to determine whether calgranulin A expression is associated with recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS).

Results

Calgranulin A expression is significantly different between pTa and pT1 tumors (p = 0.000, Mann–Whitney U test) and between tumor grades (p = 0.015, Kruskal–Wallis test). Kaplan–Meier estimates produced significant results for low and high calgranulin A expression concerning RFS [5y-RFS 70.4 ± 4.0% vs. 35.9 ± 12.5%, median RFS not reached (NR) vs. 12.0 ± 4.4 month, p = 0.029, log-rank test], PFS (5y-PFS 90.3 ± 2.7% vs. 51.5 ± 14.0%, median PFS NR in both groups, p = 0.000, log-rank test), and CSS (5y-CSS 92.9 ± 2.6% vs. 70.7 ± 12.4%, median CSS NR in both groups, p = 0.005, log-rank test). Calgranulin A remained an independent factor for RFS (p = 0.024, HR 2.43) and PFS (p = 0.002, HR 5.92) according to the multivariate Cox regression model.

Conclusions

Calgranulin A expression in NMIBC, detected through immunohistochemistry, is a promising marker for the identification of NMIBC patients at high risk of recurrence and progression.



https://ift.tt/2OBVTsb

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Abstract

Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.



https://ift.tt/2pi7rpc

Potentiating Renal Regeneration using Mesenchymal Stem Cells

Background The potential of a Mesenchymal Stem Cell (MSC) therapy to accelerate the repair of ischemically damaged human kidneys during 24 hours of warm perfusion was evaluated. The hypothesis was that by administering MSC directly to the renal tissue, there would be an improved opportunity for cellular repair mediated by intrarenal paracrine effects. Methods Studies were performed using the Exsanguinous Metabolic Support (EMS) tissue-engineering platform. Five pairs of human kidney allografts from donation after cardiac death (DCD) donors were studied. One human kidney was EMS perfused for 24 hours (control), while its paired kidney was EMS perfused with MSC (1×108). The kidneys were evaluated for DNA synthesis, cytokine/chemokine synthesis, cytoskeletal regeneration and mitosis. Results Treatment with MSC resulted in reduced inflammatory cytokines synthesized by the kidneys. MSC treatment led to a significant increase in the synthesis of ATP and growth factors resulting in normalization of metabolism and the cytoskeleton. Toluidine Blue staining of MSC treated kidneys demonstrated a significant increase in the number of renal cells undergoing mitosis (26%) compared to EMS perfusion alone. Conclusions To our knowledge, our work is the first to have demonstrated actual renal regeneration while ischemically damaged human kidneys are perfused ex vivo for 24 hours. The observed regeneration entails: increased synthesis of ATP, a reduced inflammatory response, increased synthesis of growth factors, normalization of the cytoskeleton and mitosis. The ability to regenerate renal tissue ex vivo sufficiently to result in immediate function could revolutionize transplantation by solving the chronic organ shortage. Corresponding Author: Lauren Brasile, BREONICS INC, 44 Dalliba Avenue, Watervliet NY, 12189 (lbrasile@citlink.net) Authorship: Lauren Brasile Ph.D. Participated in research design Participated in the writing of the paper Participated in the performance of the research Contributed new reagents or analytic tools Participated in data analysis Nicholas Henry BA. Participated in research design Participated in the performance of the research Participated in data analysis Giuseppe Orlando Ph.D. Participated in the writing of the paper Bart Stubenitsky MD., Ph.D. Participated in research design Participated in the writing of the paper Participated in data analysis Disclosure: The authors declare no conflicts of interest. Funding Sources: This work was funded by the National Institute of Health R43 Grant # R43AI106362-01 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2Nkm6yG

VCA Deceased Donors in the United States

Background Vascularized composite allograft (VCA) transplants include diverse organ types and are made possible primarily by deceased donors. Methods We used Organ Procurement and Transplantation Network (OPTN) data to characterize VCA deceased donors (n=66 of 70) in the United States 1998-2017 and compare their characteristics with those of kidney donors in 2017. Results Through December 31, 2017, 20 transplant programs performed 72 deceased donor VCA transplants, with organs donated by 70 donors, including 30 upper limb (17 unilateral and 13 bilateral) and 11 face donors. Other donors donated both upper limbs and face (n=2), uterus (n=4), abdominal wall (n=19), larynx (n=2), penis (n=1), and scalp (n=1). About a third of VCA donors were female, and the majority (86.4%) were white. Almost half (45.5%) were between 18 and 34 years old. Smaller proportions were under 18 (19.7%), 35-44 (15.2%), 45-54 (13.6%), and over 55 years old (6.1%). Median body mass index for all VCA donors was 24.9 and varied widely, especially for upper limb and face donors. There was considerable variation in Kidney Donor Profile Index among VCA donors (median: 27.5; interquartile range: 11-59). Donor causes of death included head trauma (39.4%), cerebrovascular/stroke (25.8%), and anoxia (31.8%). VCA donors also donated solid organs that were transplanted, including 87.1% of kidneys, 93.9% of livers, 40.2% of lungs, and 56.1% of hearts. Conclusions VCA donors are a demographically and clinically diverse group. Understanding this diversity and future trends in VCA donor characteristics is critical in supporting this life-changing field of transplantation. Corresponding Author: Jennifer L. Wainright, 700 N 4th Street, Richmond, VA 23219, jennifer.wainright@unos.org Authorship: Participated in research design: Jennifer Wainright, Christopher Wholley, John Rosendale, Wida Cherikh, David Klassen Participated in writing of paper: Jennifer Wainright, Christopher Wholley, John Rosendale, Darren Di Battista, Wida Cherikh, David Klassen Participated in performance of the research: Jennifer Wainright Participated in data analysis: Jennifer Wainright Disclosure: The authors declare no conflicts of interest. Funding: This work was conducted under the auspices of the United Network for Organ Sharing (UNOS), contractor for OPTN, under Contract 234-2005-370011C (US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2Db3YCS

Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients

Background Lung transplantation is the only therapeutic option in end stage lung diseases, however, survival after transplantation is limited by acute and chronic rejection or infectious events being results of inappropriate immunosuppression. Torque Teno Viruses (TTV) are ubiquitous DNA viruses in humans but not found to be causative for any disease. However, some reports suggest that TTV-DNA levels reflect the grade of immunosuppression with higher levels being found in more immunosuppressed individuals. Methods We investigated the TTV-DNA levels in 34 lung transplant recipients within their first year following transplantation by quantitative real-time PCR. Clinical data were extracted from charts. Results In accordance with previous results TTV-DNA levels increase after lung transplantation reaching a steady state after 3 months. TTV-DNA levels were not correlated with immunosuppressive trough levels and a selective increase was not observed with other DNA viruses. In steady state TTV-DNA levels were significantly higher in patients with infectious complications compared to the group of patients without. Additionally, TTV-DNA levels decreased significantly prior to biopsy-proven rejection. Sensitivity of a 10-fold decrease in TTV-DNA levels for a subsequent rejection episode was 0.74 with a specificity of 0.99. Conclusions In summary TTV-DNA might be used as an additional tool to monitor immunosuppression in lung transplant recipients. Higher TTV-DNA levels reflect more intense immunosuppression, whereas the TTV-DNA kinetic (ie, decrease of TTV-DNA levels) indicate rejection. Corresponding author: Dr. B. C. Frye, Department of Pneumology, University Medical Center, University of Freiburg, Killianstrasse 5, 79106 Freiburg, Phone: +49 (0)761 270 37060, Fax: +49 (0)761 270 37040. Mail: Joachim.mueller-quernheim@uniklinik-freiburg.de Authors' contribution: Research design: BCF, SB, VF, MG, HH, JMQ; Data collection: BCF, TCK, MG, IH, JMQ; Patient characterization: BCF, TCK, MG, IH, TD, MI, GZ, JMQ; Laboratory work: SB, VF, HH; Data analysis: BCF, SB, VF, GZ, HH, JMQ; Writing Paper: BCF, SB, VF, IH, GZ, HH, JMQ; Disclosure: All authors declare no conflicts of interest. Funding: No external funding Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2NodnLZ

Correction to: ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial

Following publication of the original article [1], the authors reported that one of the authors' names is spelled incorrectly. In this Correction the incorrect and correct author name are shown. The original publication of this article has been corrected.



https://ift.tt/2D91vZJ

Genotoxic and Chemopreventive Effects of Vochysia divergens Leaves (Pantanal, Brazil)

The medicinal plant Vochysia divergens is a colonizing tree species of the Pantanal, a unique and little explored wetland region in Brazil. This species is used in folk medicine as syrups and teas to treat respiratory infections, digestive disorders, asthma, scarring, and skin diseases. The objectives of this study were to evaluate the antioxidant, cytotoxic, and genotoxic potential of the ethanolic extract of Vochysia divergens leaves (VdE), as well as the influence of VdE and its major component (the flavone 3′,5-dimethoxy luteolin-7-O-β-glucopyranoside; 3′5 DL) on MMS-induced genotoxicity. The extract significantly reduced the viability of V79 cells in the colorimetric XTT assay at concentrations ≥ 39 μg/mL. A significant increase in micronucleus frequencies was observed in V79 cell cultures treated with VdE concentrations of 160 and 320 μg/mL. However, animals treated with the tested doses of VdE (500, 1000, and 2000 mg/kg b.w.) exhibited frequencies that did not differ significantly from those of the negative control group, indicating the absence of genotoxicity. The results also showed that VdE was effective in reducing MMS-induced genotoxicity at concentrations of 20, 40, and 80 μg/mL in the in vitro test system and at a dose of 15 mg/kg b.w. in the in vivo test system. Its major component 3′5 DL exerted no protective effect, suggesting that it is not responsible for the effect of the extract. The results of the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay showed that VdE was able to scavenge 92.6% of free radicals. In conclusion, the results suggest that the protective effect of VdE may be related, at least in part, to the antioxidant activity of its chemical constituents.

https://ift.tt/2NSvEAr